Search Results

Baxter Declares Quarterly Dividend

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on April 3, 2023, to shareholders of record as of February 24, 2023. The indicated annual dividend rate is $1.16 per share of common stock. About Baxter

Baxter Reports Fourth-Quarter and Full-Year 2022 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2022, and provided its financial guidance for full-year and first-quarter 2023. 

Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure

Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies. As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system.

Tapping the Potential of Device Data

There is untapped potential to connect medical devices with an analytics engine that provides actionable insights that clinicians can use as part of their decision-making process. When you equip clinicians with data when they need it, they can achieve efficiencies and avoid potentially harmful events.

Baxter to Host Fourth-Quarter 2022 Financial Results Conference Call for Investors

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2022 financial results on Thursday, February 9, 2023 at 7:30 a.m. Central Time.  To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information.

Baxter Announces Strategic Actions to Enhance Operational Effectiveness, Accelerate Innovation for Patients and Drive Value for Shareholders

Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced a comprehensive strategic roadmap to meaningfully enhance its operational effectiveness, drive toward improved long-term performance, accelerate innovation and create additional value for all stakeholders.

Mission-Driven Volunteer

Every day, Baxter strives to make a meaningful difference in the communities where our employees live and work. This commitment is embodied by our dedicated employee, Cynthia. In addition to her work as Baxter's director of clinical quality for Renal Care Services, she is also president of the board of directors for Thresholds, a non-profit organization that provides healthcare, housing and hope to persons with serious mental illnesses and substance use disorders.

Baxter Named to Dow Jones Sustainability Indices for 23rd Consecutive Year

Baxter International Inc. (NYSE: BAX), a global medtech leader, today announced it was again named to the Dow Jones Sustainability Indices (DJSI), including both DJSI World and DJSI North America. Baxter has proudly been included in the DJSI World and DJSI North America each year since they launched, in 1999 and 2005, respectively.  

Supporting Baxter’s Mission Through Digital Education

Baxter is accelerating its digital transformation by driving data, insights and partnerships to advance our mission of saving and sustaining lives.

Baxter Introduces ExactaMix Pro, Next-Generation Automated Nutrition Compounder, at ASHP Meeting

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, announces the launch of the ExactaMix Pro Automated Compounder, which is expected to be available to customers in the United States in early 2023. ExactaMix Pro will be on display at Baxter’s booth #937 at the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting taking place Dec. 4 – Dec. 8, 2022, in Las Vegas.